Search Results

You are looking at 1 - 10 of 37 items for :

  • "uterine cancer" x
Clear All
Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr and Nelson Teng

Chan JK Wu H Cheung MK . The outcomes of 27,063 women with unstaged endometrioid uterine cancer . Gynecol Oncol 2007 ; 106 : 282 – 288 . 17 Chan JK Kapp DS . Role of complete lymphadenectomy in endometrioid uterine cancer . Lancet Oncol

Full access

The University of Alabama at Birmingham Comprehensive Cancer Center

Adenocarcinoma of the endometrium is the most common malignancy of the female genital tract in the United States. Many physicians believe that adenocarcinoma of the endometrium is a relatively benign disease because of the early symptoms of irregular vaginal bleeding in this predominantly postmenopausal patient population, the often-localized nature of the disease, and the generally high survival rate. However, the estimated number of deaths from endometrial cancer continues to increase, indicating the need for a critical reassessment of the guidelines for managing endometrial cancer. Physicians must identify high-risk patients and tailor treatment appropriately to provide the best opportunity for long-term survival.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian and Miranda Hughes

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. An estimated 49,560 new uterine cancer cases

Full access

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol and Carole Corsini

Hodgkin lymphoma; pink, breast cancer; red, uterine cancer; purple, ovarian cancer; yellow, thyroid cancer; turquoise, lung cancer; carmine red, suspected liver cancer). Abbreviations: A&W, alive and well; b, born; c, PTEN variant carrier status; ca

Full access

Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul and Daniel Becker

preceding the diagnosis of uterine cancer are also rare, and only 5 similar cases have been reported ( Table 1 ). 6 , 8 , 13 - 15 The cases were predominantly in postmenopausal women, with a median age of 63.4 years, who presented at an advanced stage. The

Full access

Jennifer A. Ligibel and Eric P. Winer

Adjuvant hormonal therapy has been shown to decrease the risk of breast cancer recurrence and overall mortality in patients with hormone receptor-positive breast cancer. Tamoxifen has been used in this setting for many years, both in premenopausal and postmenopausal patients. Tamoxifen is not devoid of toxicity, and attempts have been made to develop newer hormonal agents with better efficacy and less toxicity. The aromatase inhibitors have shown equivalent or superior efficacy to tamoxifen in the treatment of metastatic breast cancer, and efforts are underway to determine the role of these agents in early breast cancer. The ATAC trial recently showed that use of the third-generation aromatase inhibitor anastrozole in the adjuvant setting led to a modest improvement in relapse-free survival as compared with tamoxifen. Patients treated with anastrozole were also less likely to develop uterine cancer or experience a thromboembolic event. However, patients treated with anastrozole were more likely than those treated with tamoxifen to suffer a fracture or other musculosketal problem. An ASCO technology assessment panel reviewed the relevant data and issued a consensus statement regarding the use of aromatase inhibitors in the adjuvant setting. In general, the panel favored the continued use of tamoxifen as adjuvant hormonal therapy for most postmenopausal women. Within the next few years, further data from the ATAC trial and from other trials of aromatase inhibitors in the adjuvant setting should be available to guide treatment recommendations for this patient population.

Full access

Goldsmith Patricia J. Paivanas Thomas MHSA 05 2006 4 4 5 5 434 434 437 437 0040434 10.6004/jnccn.2006.0036 Uterine Cancers Clinical Practice Guidelines 05 2006 4 4 5 5 438 438 438 438 0040438 10.6004/jnccn.2006.0037 Expanding Role of

Full access

rising for the most common type of uterine cancer—endometrial cancer. The newest NCCN Guidelines for Patients focuses on uterine cancers (endometrial cancer and a much rarer type called uterine sarcoma). Uterine cancers are by far the most prevalent type

Full access

Meaghan Tenney and Joan L. Walker

Piedmonte MR . Phase III trial of laparoscopy versus laparotomy for surgical resection and comprehensive surgical staging of uterine cancer: a Gynecologic Oncology Group Study funded by the National Cancer Institute . Presented at the 37th Annual Meeting

Full access

Ernest S. Han and Mark Wakabayashi

on uterine and cervical cancers. Most studies involve nonrandomized retrospective reviews of institutional experiences. A recent phase III trial comparing laparoscopy to laparotomy for uterine cancer staging in 1682 patients reported that the